HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lower dose of transplant drug boost quality of life for older cancer patients?
Disease control Recruiting nowThis study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard dose of a drug (cyclophosphamide) to a lower dose, both given after transplant to prevent graft-versus-host disease (GVHD), a common complication where donor cell…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New antibody drug shows promise for Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 participants will receive the drug to see…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 04:14 UTC
-
New drug combo targets blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ICP-248, alone or with another drug, for people with certain blood cancers (B-cell malignancies). The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 191 adults aged 18 to 80 will take part.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug DS3790a shows promise in early blood cancer trial
Disease control Recruiting nowThis study tests a new drug called DS3790a in people with blood cancers like leukemia or lymphoma. The main goals are to check safety and see if the drug can shrink tumors. About 420 adults will take part, and the drug is given alone or with other treatments.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New pill HMPL-506 enters human trials for tough blood cancers
Disease control Recruiting nowThis early-stage study tests an experimental pill called HMPL-506 in about 132 adults with certain blood cancers (like AML and ALL) that have come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink or c…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests a program where nurses start conversations about palliative care early for children with cancer. The goal is to see if this improves the child's quality of life and reduces side effects. About 120 children and their families will take part, with some getting the …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC
-
Massive study seeks genetic clues in early blood cancers
Knowledge-focused Recruiting nowThis study aims to find genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or tissue samples from up to 10,000 participants to understand how these changes cause cancer to progress. The goal…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated May 17, 2026 04:15 UTC
-
15-Year watch begins for CAR T-Cell therapy patients
Knowledge-focused Recruiting nowThis study follows people who have already been treated with a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring. About 546 participan…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: Galapagos NV • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC